HABP4: A Potential Drug Target and Biomarker (G22927)

Target Name: HABP4

NCBI ID: G22927

HABP4

HABP4: A Potential Drug Target and Biomarker

Hematopoietic antigen-B (HABP4) is a protein that is expressed in various tissues and cells, including the hematopoietic stem cells, peripheral blood cells, and the spleen. It is a member of the T-cell receptor (TCR) family and is involved in the development and maintenance of the immune system. Unfortunately, HABP4 has also been implicated in the development of various diseases, including cancer.

One of the main challenges in studying HABP4 is its complex biology. While it is known to be involved in the immune response, its exact function and how it contributes to the development of disease is not well understood. This is where the development of monoclonal antibodies (MAbs) has become a valuable tool.

Monoclonal antibodies are a type of immunoglobulin that are produced by mice or other animals and can detect a specific antigen with high sensitivity and specificity. By using MAbs to target HABP4, researchers have been able to study its biology in greater detail and determine its potential as a drug target or biomarker.

One of the most promising applications of HABP4 as a drug target is its involvement in cancer. Cancer is a disease that can be treated with monoclonal antibodies, and HABP4 has been shown to be involved in the development and progression of various types of cancer. For For example, studies have shown that HABP4 is expressed in various types of cancer, including lung cancer, breast cancer, and colon cancer.

In addition to its potential as a cancer drug target, HABP4 has also been shown to be a potential biomarker for the disease. Its expression has been detected in various types of cancer, as well as in diseases that are not cancer-related, such as autoimmune disorders and inflammation. This suggests that HABP4 may be a useful biomarker for tracking the progression of disease and evaluating the effectiveness of cancer treatments.

Another potential application of HABP4 as a drug target is its involvement in autoimmune disorders. HABP4 has been shown to be involved in the development and maintenance of autoimmune disorders, and may play a role in the development of these conditions. For example, studies have shown that HABP4 is expressed in a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

In addition to its potential as a drug target or biomarker, HABP4 has also been shown to have potential therapeutic applications in other areas. For example, it has been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of the immune system. In addition, HABP4 has been shown to play a role in the regulation of cellular processes that are important for the development and maintenance of tissues and organs.

Overall, HABP4 is a protein that has the potential to be a drug target or biomarker in a variety of diseases. While more research is needed to fully understand its biology and its potential applications, its complex biology and involvement in various diseases make it an intriguing target for further study. As research continues to progress, HABP4 may emerge as a valuable tool for the development of new treatments for a variety of diseases.

Protein Name: Hyaluronan Binding Protein 4

Functions: RNA-binding protein that plays a role in the regulation of transcription, pre-mRNA splicing and mRNA translation (PubMed:14699138, PubMed:16455055, PubMed:19523114, PubMed:21771594). Negatively regulates DNA-binding activity of the transcription factor MEF2C in myocardial cells in response to mechanical stress (By similarity). Plays a role in pre-mRNA splicing regulation (PubMed:19523114). Binds (via C-terminus) to poly(U) RNA (PubMed:19523114). Involved in mRNA translation regulation, probably at the initiation step (PubMed:21771594). Seems to play a role in PML-nuclear bodies formation (PubMed:28695742)

The "HABP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HABP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets